β-catenin regulates NF-κB activity via TNFRSF19 in colorectal cancer cells

International Journal of Cancer

Volumn 135, Issue 8, 2014, Pages 1800-1811

  Schön, Simon ^a   Flierman, Isabelle ^a   Ofner, Andrea ^a   Stahringer, Anika ^a   Holdt, Lesca Miriam ^a   Kolligs, Frank T ^a   Herbst, Andreas ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

beta catenin; colorectal cancer; NFkappaB; TNFRSF19; TROY

Indexed keywords

BETA CATENIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN TNFRSF19; PROTEIN TNFRSF19.1; PROTEIN TNFRSF19.2; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CROHN DISEASE; EMBRYO; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TNFRSF19 GENE; ULCERATIVE COLITIS;

BETA-CATENIN; COLORECTAL CANCER; NFKAPPAB; TNFRSF19; TROY;

BETA CATENIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEK293 CELLS; HUMANS; NF-KAPPA B; PROMOTER REGIONS, GENETIC; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84905743985     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28839     Document Type: Article

References (34)

1. Giles RH, van Es JH, Clevers H,. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003; 1653: 1-24.
2. Reya T, Clevers H,. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-50.
3. Ilyas M,. Wnt signalling and the mechanistic basis of tumour development. J Pathol 2005; 205: 130-44.
4. Clevers H,. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-80.
5. Jass JR,. Colorectal cancer: a multipathway disease. Crit Rev Oncog 2006; 12: 273-87.
6. Qiu W, Hu Y, Andersen TE, et al. Tumor necrosis factor receptor superfamily member 19 (TNFRSF19) regulates differentiation fate of human mesenchymal (stromal) stem cells through canonical Wnt signaling and C/EBP. J Biol Chem 2010; 285: 14438-49.
7. De Toni EN, Thieme SE, Herbst A, et al. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res 2008; 14: 4713-8.
8. Kojima T, Morikawa Y, Copeland NG, et al. TROY, a newly identified member of the tumor necrosis factor receptor superfamily, exhibits a homology with Edar and is expressed in embryonic skin and hair follicles. J Biol Chem 2000; 275: 20742-7.
9. Aggarwal BB,. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-56.
10. Gaur U, Aggarwal BB,. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003; 66: 1403-8.
11. Locksley RM, Killeen N, Lenardo MJ,. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
12. Paulino VM, Yang Z, Kloss J, et al. TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling. Mol Cancer Res 2010; 8: 1558-67.
13. Eby MT, Jasmin A, Kumar A, et al. TAJ, a novel member of the tumor necrosis factor receptor family, activates the c-Jun N-terminal kinase pathway and mediates caspase-independent cell death. J Biol Chem 2000; 275: 15336-42.
14. Hashimoto T, Schlessinger D, Cui C-Y,. Troy binding to lymphotoxin-alpha activates NF kappa B mediated transcription. Cell Cycle 2008; 7: 106-11.
15. Pispa J, Mikkola ML, Mustonen T, et al. Ectodysplasin, Edar and TNFRSF19 are expressed in complementary and overlapping patterns during mouse embryogenesis. Gene Expr Patterns 2003; 3: 675-9.
16. Hu S, Tamada K, Ni J, et al. Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily. Genomics 1999; 62: 103-7.
17. Hisaoka T, Morikawa Y, Kitamura T, et al. Expression of a member of tumor necrosis factor receptor superfamily, TROY, in the developing mouse brain. Brain Res Dev Brain Res 2003; 143: 105-9.
18. Spanjaard RA, Whren KM, Graves C, et al. Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target. Int J Cancer 2007; 120: 1304-10.
19. Wang Y, Li X, Wang L, et al. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J Cell Sci 2004; 117: 1525-32.
20. Shao Z, Browning JL, Lee X, et al. TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 2005; 45: 353-9.
21. Park JB, Yiu G, Kaneko S, et al. A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron 2005; 45: 345-51.
22. Kolligs FT, Kolligs B, Hajra KM, et al. gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 2000; 14: 1319-31.
23. Herbst A, Bommer GT, Kriegl L, et al. ITF-2 is disrupted via allelic loss of chromosome 18q21, and ITF-2B expression is lost at the adenoma-carcinoma transition. Gastroenterology 2009; 137: 639-48.
24. Tetsu O, McCormick F,. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-6.
25. Arenzana-Seisdedos F, Fernandez B, Dominguez I, et al. Phosphatidylcholine hydrolysis activates NF-kappa B and increases human immunodeficiency virus replication in human monocytes and T lymphocytes. J Virol 1993; 67: 6596-604.
26. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
27. van de Wetering M, Oosterwegel M, Dooijes D, et al. Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box. EMBO J 1991; 10: 123-32.
28. Paradisi A, Maisse C, Bernet A, et al. NF-kappaB regulates netrin-1 expression and affects the conditional tumor suppressive activity of the netrin-1 receptors. Gastroenterology 2008; 135: 1248-57.
29. Horst D, Budczies J, Brabletz T, et al. Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer. Cancer 2009; 115: 4946-58.
30. Deng J, Miller SA, Wang H-Y, et al. beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2002; 2: 323-34.
31. Naugler WE, Karin M,. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18: 19-26.
32. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
33. Rigby RJ, Simmons JG, Greenhalgh CJ, et al. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 2007; 26: 4833-41.
34. Luo J-L, Maeda S, Hsu L-C, et al. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004; 6: 297-305.